ES2194054T3 - Compuestos de lactona macrociclica y su procedimiento de produccion. - Google Patents

Compuestos de lactona macrociclica y su procedimiento de produccion.

Info

Publication number
ES2194054T3
ES2194054T3 ES95932876T ES95932876T ES2194054T3 ES 2194054 T3 ES2194054 T3 ES 2194054T3 ES 95932876 T ES95932876 T ES 95932876T ES 95932876 T ES95932876 T ES 95932876T ES 2194054 T3 ES2194054 T3 ES 2194054T3
Authority
ES
Spain
Prior art keywords
macrociclic
production procedure
lactone compounds
lactone
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932876T
Other languages
English (en)
Inventor
H Nishida
Y Yamauchi
T-Pfizer Phar Inagaki
Y Kojima
N Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2194054T3 publication Critical patent/ES2194054T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

ESTA INVENCION DESCRIBE UN PROCEDIMIENTO PARA PRODUCIR UN COMPUESTO DE LACTONA MACROCICLICA QUE INCLUYE CULTIVAR ACTINOPLANES SP. FERM BP - 3832, EN PRESENCIA DE L - PROLINA, L HIDROXIPROLINA O ACIDO L - NIPECOTICO, Y DESPUES AISLAR UN COMPUESTO DE LACTONA MACROCICLICA A PARTIR DEL CALDO DE FERMENTACION. LOS COMPUESTOS PRODUCIDOS MEDIANTE ESTE PROCEDIMIENTO INCLUYEN UN COMPUESTO DE FORMULA (I). LA PRESENTE INVENCION TAMBIEN TRATA DE UNA COMPOSICION FARMACEUTICA QUE INCLUYE EL MISMO, QUE RESULTA UTIL COMO AGENTE INMUNOSUPRESOR, ANTIMICOTICO, ANTITUMORAL O SIMILARES.
ES95932876T 1994-11-10 1995-10-13 Compuestos de lactona macrociclica y su procedimiento de produccion. Expired - Lifetime ES2194054T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9401896 1994-11-10
PCT/IB1995/000870 WO1996015131A1 (en) 1994-11-10 1995-10-13 Macrocyclic lactone compounds and their production process

Publications (1)

Publication Number Publication Date
ES2194054T3 true ES2194054T3 (es) 2003-11-16

Family

ID=1341416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932876T Expired - Lifetime ES2194054T3 (es) 1994-11-10 1995-10-13 Compuestos de lactona macrociclica y su procedimiento de produccion.

Country Status (12)

Country Link
US (2) US6001998A (es)
EP (1) EP0854874B1 (es)
JP (1) JP3061863B2 (es)
AT (1) ATE239024T1 (es)
CA (1) CA2204739C (es)
DE (1) DE69530616T2 (es)
DK (1) DK0854874T3 (es)
ES (1) ES2194054T3 (es)
FI (1) FI971995A0 (es)
MX (1) MX9703484A (es)
PT (1) PT854874E (es)
WO (1) WO1996015131A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204739C (en) * 1994-11-10 2000-04-04 Hiroyuki Nishida Macrocyclic lactone compounds and their production process
ATE411019T1 (de) * 2001-05-02 2008-10-15 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US6551591B1 (en) 2001-09-07 2003-04-22 Essential Therapeutics, Inc. Antibiotics from microbispora
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
CN1946656B (zh) * 2004-02-17 2011-08-24 托马斯·E·约翰逊 形成大环化合物的方法、组合物和设备
TW201206425A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2598805A1 (en) * 2005-02-24 2006-08-31 Biocern, Inc. Sperm cell separation methods and compositions
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
US20070054890A1 (en) * 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
CA2659242C (en) 2006-07-28 2015-08-11 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
CA2697960A1 (en) * 2006-08-30 2008-03-06 Biocern, Inc. Sperm cell separation methods and compositions containing aptamers or nucleic acid sequences for use therein
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2121001B1 (en) 2007-02-09 2014-12-17 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins on ischemia/stroke-induced memory impairment and brain injury
KR20140049054A (ko) * 2007-02-09 2014-04-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
US8410066B2 (en) * 2009-05-01 2013-04-02 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
JP5833007B2 (ja) * 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
US9107890B2 (en) 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
JP6422778B2 (ja) 2011-11-13 2018-11-14 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃアクチベーターおよびその組合せ
JP2018521113A (ja) 2015-05-11 2018-08-02 アルコン、ダニエル・エル． ＡｐｏＥ４対立遺伝子の存在を決定した後のＰＫＣ活性化因子を使用した神経変性状態の治療
CN107827803A (zh) * 2017-11-28 2018-03-23 绍兴厚普生物科技有限责任公司 一种从发酵液中提取l‑羟脯氨酸的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6903238A (es) * 1968-03-04 1969-09-08
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5674732A (en) * 1992-04-27 1997-10-07 Pfizer Inc. Rapamycin producer
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
CA2204739C (en) * 1994-11-10 2000-04-04 Hiroyuki Nishida Macrocyclic lactone compounds and their production process

Also Published As

Publication number Publication date
EP0854874A1 (en) 1998-07-29
ATE239024T1 (de) 2003-05-15
PT854874E (pt) 2003-07-31
DK0854874T3 (da) 2003-06-02
MX9703484A (es) 1997-08-30
CA2204739C (en) 2000-04-04
FI971995L (fi) 1997-05-09
US6001998A (en) 1999-12-14
JP3061863B2 (ja) 2000-07-10
DE69530616D1 (de) 2003-06-05
FI971995A7 (fi) 1997-05-09
EP0854874B1 (en) 2003-05-02
US6187568B1 (en) 2001-02-13
JPH11507907A (ja) 1999-07-13
WO1996015131A1 (en) 1996-05-23
DE69530616T2 (de) 2004-04-01
FI971995A0 (fi) 1997-05-09

Similar Documents

Publication Publication Date Title
MX9703484A (es) Compuestos de lactona macrociclicos y su procedimiento de produccion.
ES2152701T3 (es) Composiciones acuosas desinfectantes y de limpieza.
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
ES2160125T3 (es) Proceso para la sintesis de azetidinonas.
AR002061A1 (es) Compuesto elastomerico que incorpora negro de carbon recubierto parcialmente, un articulo formado a partir de dicho compuesto, una formulacionque lo contiene y un metodo para mejorar la histeresis.
ES2105913T3 (es) Composiciones para el teñido de las fibras queratinicas que comprenden un orto-diamino pirazol y una sal de manganeso, procedimiento de teñido que utiliza estas composiciones.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
DE69526854D1 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
ATE232907T1 (de) Enantiosektive herstellung pharmazeutisch aktiver sulfoxide durch biooxidation
MX2021010875A (es) Composiciones de éster de ácido cannabinoide y sus usos.
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
ES2125535T5 (es) Mezclas, que contienen isocianatos emulsionables en agua.
ES2117281T3 (es) Nuevos analogos de la vitamina d.
ES2173194T3 (es) Procedimiento de racemizacion utilizado para la preparacion de levobupivacaina y sus analogos.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
ES2150705T3 (es) Derivados de ester de nitrito esteroideos utiles como farmacos antiinflamatorios.
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
ES2149931T3 (es) Procedimiento para la produccion de xilitol.
DE69905700D1 (de) Desinfizierende Zusammensetzung
ES2181846T3 (es) Un procedimiento para preparar dioles utilizando un catalizador de niquel raney modificado.
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
BR9506866A (pt) Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a
ES2116634T3 (es) Nuevo empleo de 1alfa-fluoro-25-hidroxi-16-en-23-in-colecalciferol.
ES2142490T3 (es) Ciclopeptolidos.